CNTB Connect Biopharma (CNTB) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001835268
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
40
13F, latest reported quarter
What the filings say about CNTB
Insiders, 180 days
+$372.0K net bought
1 buyer
Connect Biopharma insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Connect Biopharma Holdings Ltd insiders bought a net $372.0K of stock across 2 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Mar 31, 2026.
- The trade is 1.1% of the 13,310,000 shares held after it.
- No other insider bought within 30 days.
- 40 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Huang James bought about $372.0K of CNTB on May 29, 2026; 40 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 8.8% of the 13,160,000 shares held after it.
- No other insider bought within 30 days.
- 40 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Huang James bought about $4.0M of CNTB on Mar 31, 2026, the largest insider purchase at the company on our record; 40 funds added in the latest 13F quarter.2 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$372.0K over 180 days
more than 84% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
40 funds bought in last quarter
below 57% of Pharma & Biotech
Revenue
-99.8% year over year
below 92% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
20.2% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
more than 53% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch CNTB
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-47.6%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CNTB: institutional holders (13F)
13F holdings, latest reported quarter
4,538,534 sh
$10.8M
1,285,000 sh
$3.1M
973,732 sh
$2.3M
871,653 sh
$2.1M
792,696 sh
$1.9M
Congress trades in CNTB
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CNTB planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
CNTB mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Small Cap Index Fund
$19.5K position · as of 2026-06-30
0.0%
Nuveen Small Cap Blend Index Fund
$39.9K position · as of 2026-07-31
0.0%
Global X Russell 2000 ETF
$14.4K position · as of 2026-07-31
0.0%
PROFUND VP SMALL CAP
$95 position · as of 2026-06-30
0.0%
PROFUND VP ULTRA SMALL CAP
$148 position · as of 2026-06-30
0.0%
ULTRA SMALL CAP PROFUND
$390 position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $372.0K bought by insiders over 180 days, 40 funds added last quarter. Each figure is a federal filing, dated the day it went public.
CNTB financials
Revenue growth
-99.8%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$3.0M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM CNTB
| FY Dec 2025 | $64.0K |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $2.8M |
| Mar 2026 | $169.0K |
| Dec 2025 | $0 |
| Sep 2025 | $16.0K |
| Jun 2025 | $48.0K |
| Mar 2025 | $0 |
| Dec 2024 | $698.0K |
| Sep 2024 | $1.2M |
At each fiscal year end
Single quarter
Net margin, TTM
-2,336%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM CNTB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -624.4% |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -1,276% |
| Sep 2024 | -1,056% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$60.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CNTB
| FY Dec 2025 | -$51.6M |
| FY Dec 2024 | -$24.4M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -$15.9M |
| Mar 2026 | -$16.0M |
| Dec 2025 | -$11.3M |
| Sep 2025 | -$17.4M |
| Jun 2025 | -$12.9M |
| Mar 2025 | -$10.0M |
| Dec 2024 | -$2.6M |
| Sep 2024 | -$13.2M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity CNTB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt CNTB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-140.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CNTB
| FY Dec 2025 | -82.7% |
| FY Dec 2024 | -16.1% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -140.5% |
| Mar 2026 | -102.9% |
| Dec 2025 | -82.7% |
| Sep 2025 | -63.2% |
| Jun 2025 | -49.3% |
| Mar 2025 | -19.5% |
| Dec 2024 | -16.1% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-109.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CNTB
| FY Dec 2025 | -70.5% |
| FY Dec 2024 | -13.7% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -109.3% |
| Mar 2026 | -84.6% |
| Dec 2025 | -70.5% |
| Sep 2025 | -73.2% |
| Jun 2025 | -44.2% |
| Mar 2025 | -18.6% |
| Dec 2024 | -13.7% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital CNTB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-142.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CNTB
| FY Dec 2025 | -85.9% |
| FY Dec 2024 | -23.0% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -142.0% |
| Mar 2026 | -104.2% |
| Dec 2025 | -85.9% |
| Sep 2025 | -93.3% |
| Jun 2025 | -53.2% |
| Mar 2025 | -25.3% |
| Dec 2024 | -23.0% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing CNTB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value CNTB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-113.4%
TTM free cash flow over market value at close 2026-10-26
FCF yield CNTB
| FY Dec 2025 | -32.8% |
| FY Dec 2024 | -32.0% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -40.5% |
| Mar 2026 | -38.9% |
| Dec 2025 | -32.8% |
| Sep 2025 | -51.1% |
| Jun 2025 | -71.1% |
| Mar 2025 | -111.1% |
| Dec 2024 | -32.0% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing CNTB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $64.0K | $26.0M | $0 | n/a |
| Operating income | -$58.1M | -$22.5M | -$69.1M | n/a |
| Net income | -$55.5M | -$15.6M | -$62.1M | -$118.1M |
| EPS (diluted) | -1.00 | -0.28 | -1.13 | n/a |
| Operating cash flow | -$51.2M | -$23.6M | -$47.7M | n/a |
| Cash | $38.3M | $78.2M | $105.7M | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
CNTB Stock Sonar score 5/7 axes
Find similar shapesCompareCNTB ranks highest on insider conviction (70th percentile) and institutional and government (43rd), and lowest on growth (8th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CNTB filings, in plain words
Are Connect Biopharma insiders buying or selling CNTB?
In the 180 days to 2026-10-28, Connect Biopharma insiders were net buyers, a net $372.0K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, Connect Biopharma insiders were net buyers of CNTB, a net $372.0K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
